title: Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?
abstract: Antimicrobial susceptibility testing (AST) assigns pathogens to "susceptible" or "resistant" clinical categories based on clinical breakpoints (CBPs) derived from MICs or inhibition zone diameters and indicates the likelihood for therapeutic success. AST reports do not provide quantitative measures for the reliability of such categorization. Thus, it is currently impossible for clinicians to estimate the technical forecast uncertainty of an AST result regarding clinical categorization. AST error rates depend on the localization of pathogen populations in relation to CBPs. Bacterial species are, however, not homogeneous, and subpopulations behave differently with respect to AST results. We addressed how AST reporting errors differ between isolates with and without acquired drug resistance determinants. Using as an example the beta-lactams and their most important resistance mechanisms, we analyzed different pathogen populations for their individual reporting error probabilities. Categorization error rates were significantly higher for bacterial populations harboring resistance mechanisms than for the wild-type population. Reporting errors for amoxicillin-clavulanic acid and piperacillin-tazobactam in Escherichia coli infection cases were almost exclusively due to the presence of broad-spectrum- and extended-spectrum-beta-lactamase (ESBL)-producing microorganisms (79% and 20% of all errors, respectively). Clinicians should be aware of the significantly increased risk of erroneous AST reports for isolates producing beta-lactamases, particularly ESBL and AmpC. Including probability indicators for interpretation would improve AST reports.
authors.affiliation: Institut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland.
authors.forename: Florian P
authors.initials: FP
authors.lastname: Maurer
authors.affiliation: Unite des Agents Antibactériens, Institut Pasteur, Paris, France.
authors.forename: Patrice
authors.initials: P
authors.lastname: Courvalin
authors.affiliation: Institut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland.
authors.forename: Erik C
authors.initials: EC
authors.lastname: Böttger
authors.affiliation: Institut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland mhombach@imm.uzh.ch.
authors.forename: Michael
authors.initials: M
authors.lastname: Hombach
mesh_terms: D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D011307:Drug Prescriptions; D005544:Forecasting / Q000379:methods*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*
references.citation: Clin Infect Dis. 2012 Jan 15;54(2):167-74
references.pmid: 22057701
references.citation: J Antimicrob Chemother. 2014 Apr;69(4):871-80
references.pmid: 24265230
references.citation: Clin Infect Dis. 2013 May;56(9):1301-9
references.pmid: 23334813
references.citation: Clin Microbiol Infect. 2013 Feb;19(2):141-60
references.pmid: 22117544
references.citation: Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents
references.pmid: 17630331
references.citation: J Antimicrob Chemother. 2010 Aug;65(8):1664-71
references.pmid: 20542902
references.citation: J Antimicrob Chemother. 2012 Jul;67(7):1569-77
references.pmid: 22461311
references.citation: Int J Antimicrob Agents. 2011 Oct;38(4):281-90
references.pmid: 21640560
references.citation: Clin Microbiol Infect. 2012 Dec;18(12):1194-204
references.pmid: 22264296
references.citation: Clin Infect Dis. 2013 Feb;56(4):488-95
references.pmid: 23090931
references.citation: Evolution. 2012 Mar;66(3):933-939
references.pmid: 22380453
references.citation: Mol Biotechnol. 1999 Dec 1;13(2):89-111
references.pmid: 10934525
references.citation: J Antimicrob Chemother. 2001 Jul;48 Suppl 1:87-102
references.pmid: 11420342
references.citation: Clin Microbiol Infect. 1996 Feb;2 Suppl 1:S26-S34
references.pmid: 11866859
references.citation: Clin Microbiol Infect. 2006 May;12(5):418-25
references.pmid: 16643517
references.citation: Clin Microbiol Infect. 2013 Feb;19(2):E59-71
references.pmid: 23210931
references.citation: J Clin Microbiol. 2011 Aug;49(8):2798-803
references.pmid: 21632895
references.citation: J Antimicrob Chemother. 2010 Jul;65(7):1319-21
references.pmid: 20395214
references.citation: Clin Microbiol Infect. 2005 Nov;11 Suppl 6:10-7
references.pmid: 16209701
references.citation: Clin Microbiol Rev. 2010 Jan;23(1):160-201
references.pmid: 20065329
references.citation: Scand J Infect Dis. 2002;34(8):567-73
references.pmid: 12238570
references.citation: J Antimicrob Chemother. 2008 Nov;62 Suppl 2:ii105-14
references.pmid: 18819975
references.citation: J Clin Microbiol. 2009 Jun;47(6):1631-9
references.pmid: 19386850
references.citation: Int J Antimicrob Agents. 2003 Jul;22(1):7-13
references.pmid: 12842323
references.citation: J Infect. 2011 Aug;63(2):114-23
references.pmid: 21669223
references.citation: Clin Infect Dis. 2004 Jul 1;39(1):31-7
references.pmid: 15206050
references.citation: J Antimicrob Chemother. 2013 Sep;68(9):2092-8
references.pmid: 23633681
references.citation: Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7
references.pmid: 22290982
references.citation: BMC Microbiol. 2013 Oct 08;13:225
references.pmid: 24099061
references.citation: Clin Microbiol Rev. 2011 Jul;24(3):515-56
references.pmid: 21734247